A Phase I Study of HS-10516 in Patients With VHL Syndrome Associated Tumors, to Investigate Safety, Tolerance, Pharmacokinetic and Efficacy
Latest Information Update: 19 Aug 2024
At a glance
- Drugs NKT 2152 (Primary)
- Indications Clear cell sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 19 Aug 2024 New trial record